Extended Data Fig. 5: Adverse events summary.From: CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialAdverse events with a Gradeā„3 incidence rate of 5% or higher were included. CAR specific toxicities were included regardless of incidence.Back to article page